Dermapharm Holding Equity 2024

Dermapharm Holding Aktienanalyse

What does Dermapharm Holding do?

Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich. Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications. The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products. Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products. Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women. Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils. Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products. Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Dermapharm Holding's Equity

Dermapharm Holding's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Dermapharm Holding's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Dermapharm Holding's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Dermapharm Holding's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Dermapharm Holding’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Dermapharm Holding stock

What is the equity of Dermapharm Holding this year?

Dermapharm Holding has equity of 539.21 M EUR this year.

What was the equity of Dermapharm Holding compared to the previous year?

The equity of Dermapharm Holding has increased/decreased by 1.43% increased compared to the previous year.

What impact does a high equity have on investors of Dermapharm Holding?

A high equity is advantageous for investors of Dermapharm Holding as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Dermapharm Holding?

A low equity can be a risk for investors of Dermapharm Holding, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Dermapharm Holding affect the company?

An increase in equity of Dermapharm Holding can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Dermapharm Holding affect the company?

A reduction in equity of Dermapharm Holding can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Dermapharm Holding?

Some factors that can affect the equity of Dermapharm Holding include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Dermapharm Holding so important for investors?

The equity of Dermapharm Holding is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Dermapharm Holding take to change the equity?

To change equity, Dermapharm Holding can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Dermapharm Holding pay?

Over the past 12 months, Dermapharm Holding paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 2.92 %. For the coming 12 months, Dermapharm Holding is expected to pay a dividend of 1.14 EUR.

What is the dividend yield of Dermapharm Holding?

The current dividend yield of Dermapharm Holding is 2.92 %.

When does Dermapharm Holding pay dividends?

Dermapharm Holding pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Dermapharm Holding?

Dermapharm Holding paid dividends every year for the past 0 years.

What is the dividend of Dermapharm Holding?

For the upcoming 12 months, dividends amounting to 1.14 EUR are expected. This corresponds to a dividend yield of 3.18 %.

In which sector is Dermapharm Holding located?

Dermapharm Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dermapharm Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dermapharm Holding from 7/2/2024 amounting to 0.88 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Dermapharm Holding pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Dermapharm Holding in the year 2023?

In the year 2023, Dermapharm Holding distributed 2.17 EUR as dividends.

In which currency does Dermapharm Holding pay out the dividend?

The dividends of Dermapharm Holding are distributed in EUR.